| Description |
NITD-688 is an orally active pan-serotype inhibitor of the dengue virus NS4B protein. NITD-688 can be used in the research of dengue virus (DENV)[1].
|
| Related Catalog |
|
| Target |
NS4B[1]
|
| In Vitro |
NITD-688 shows antiviral activity against all four serotypes of dengue virus (DENV), with EC50 values of 8 to 38 nM[1]. NITD-688 shows antiviral activity against DENV-2 infected PBMCs, with an EC50 value of 0.94 nM[1]. NITD-688 directly binds to wild-type but not mutant NS4B protein[1].
|
| In Vivo |
NITD-688 (30 mg/kg, oral gavage, twice daily for 3 days) demonstrates excellent antiviral efficacy in infected AG129 mice[1]. NITD-688 (15-300 mg/kg, oral gavage, per day for 7 days) is well tolerated in rats and dogs (toxicology studies)[1]. Animal Model: Infected AG129 mice[1] Dosage: 30 mg/kg Administration: Oral gavage, twice daily for 3 days Result: Resulted in a 1.16-log reduction in viremia.
|
